• news.cision.com/
  • Axelar AB/
  • Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717
English

Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717

Report this content

Stockholm, Sweden 2008-06-17 - STOCKHOLM, SWEDEN - Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor- 1 (IGF-1) receptor inhibitor. The phase I/II clinical trial is primarily designed to assess the  safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects will be documented whenever possible and the study will be conducted in Sweden.

See PDF